BPC-157
10 mg vial, 60 capsules
Across every published study, the retatrutide side effects seen most often involve the digestive tract. Nausea, diarrhoea, vomiting and constipation dominate the tables, they become more common as the dose climbs, and they bunch up during escalation. Two further signals deserve attention. Resting heart rate went up in step with dose, and the larger phase 3 studies surfaced dysesthesia, an altered skin sensation that phase 2 never flagged. This guide works through the trials one theme at a time and is clear about what remains unknown.
Retatrutide is one peptide built to switch on three receptors together, GIP, GLP-1 and glucagon. Eli Lilly developed it under the code LY3437943 and is the sponsor of every trial, which means all current safety knowledge flows from a single company's programme. The drug remains investigational. Without any regulatory approval there is also no post-marketing surveillance, unlike semaglutide or tirzepatide, where real-world reporting has built up over years.
The figures on this page draw on the following sources.
Several phase 3 results are still company toplines rather than full peer-reviewed papers, so the percentages quoted from them should be treated as early figures. Readers new to the molecule may want our explainer on what retatrutide is and how it works before going further.
GLP-1 receptor activation reliably unsettles the gut, and retatrutide is no exception. Digestive events top the adverse event list in each trial reported so far. In the phase 2 obesity study they consisted of nausea, diarrhoea, vomiting and constipation, mostly graded mild or moderate, more frequent at the higher doses and clustered in the escalation phase.
TRIUMPH-1 supplies the sharpest numbers. Over 80 weeks, Lilly reported the following rates for placebo and for the 12 mg dose.
| Event in TRIUMPH-1 | Placebo group | 12 mg retatrutide group |
|---|---|---|
| Nausea | 14.8% | 42.4% |
| Diarrhoea | 13.5% | 32.0% |
| Constipation | 10.9% | 26.1% |
| Vomiting | 4.8% | 25.3% |
The 40-week diabetes study TRANSCEND-T2D-1 reported smaller numbers. Placebo saw nausea in 3.7%, against 16.4% at 4 mg, 19.5% at 9 mg and 26.5% at 12 mg, while vomiting sat at 15.0% to 17.6% on drug and 2.2% on placebo. Different populations, study lengths and escalation schedules explain much of the gap, so the fair comparison is always within one trial, not between two.
Researchers on the phase 2 obesity trial built a direct test of starting dose into the design. Within the 4 mg and 8 mg groups, part of each cohort opened on 2 mg and the rest on 4 mg. The lower starting point trimmed gastrointestinal events to some degree, and phase 3 therefore moved to a gradual, stepwise approach. In TRANSCEND-T2D-1, for instance, dosing reportedly began at 2 mg and went up once every four weeks.
These details describe medically supervised trial protocols and appear here purely as study design, never as a plan for anyone to copy. What a reader should take from them is simpler. Any tolerability figure depends heavily on how fast the dose was increased, and a percentage quoted in isolation, stripped of the schedule behind it, is close to meaningless.
A faster resting pulse is a class effect of GLP-1 based drugs, and retatrutide shows it too. In phase 2 obesity data the rise scaled with dose, topped out around week 24 and then settled. Reports on that study describe a maximum gain somewhere near 5 to 10 beats per minute at the higher doses.
Hard cardiovascular outcomes are another matter, and that answer has not arrived. Participants in TRIUMPH-3 already had cardiovascular disease as well as obesity, and analysts reviewing the July 2026 readout counted 27 major adverse cardiovascular events on retatrutide versus 23 on placebo, while warning that such small numbers support no conclusion. A purpose-built heart and kidney outcomes study, TRIUMPH-Outcomes, has not yet reported. Among its Australian centres are The Alfred, Royal North Shore and Fiona Stanley hospitals.
In our view this finding is the most underreported. Dysesthesia describes skin that feels wrong, for instance tingling, burning or heightened touch sensitivity. Phase 2 raised no flag for it. TRIUMPH-4 changed that, recording it for 20.9% of participants on 12 mg and 8.8% on 9 mg while only 0.7% of the placebo group reported it. Cases were largely mild, and few people withdrew over it.
TRIUMPH-1 saw it in around one participant in ten at the top doses, and TRANSCEND-T2D-1 in 2.3% to 4.5% of retatrutide arms with no placebo cases at all. Published data have not yet explained why it happens. When an effect only shows itself after thousands of people have been dosed, it says a lot about the limited reach of a phase 2 safety table.
Withdrawal for adverse events may be the single most revealing tolerability measure, because it records people for whom the effects were bad enough to leave. Reported discontinuation figures were as follows.
Beta-hydroxybutyrate rose in the liver fat substudy, yet no ketoacidosis appeared, and over 48 weeks there was no hepatotoxicity signal. Across the full programme the same trend repeats. The top dose is the hardest to tolerate, and 12 mg loses noticeably more participants than 4 mg.
Is retatrutide safe? That cannot be answered until a regulator has finished assessing it, and none has. The unknowns are substantial.
Australia also faces a problem unrelated to the molecule itself. Victoria's Department of Health announced in June 2026 that, since January, acute liver injury had struck six users of unapproved products carrying retatrutide labels, with a contaminant named as a possible factor. Three months later the TGA described a so-called retatrutide product, connected to a hospital case involving a torn oesophagus, that turned out to contain zero retatrutide and a heavy load of undeclared semaglutide. According to the TGA, nobody should use retatrutide except within a clinical trial.
Those Australian cases explain why any laboratory handling retatrutide needs proof of what is in the vial. Semaglutide and retatrutide have different molecular masses, so a swapped product shows up immediately on mass spectrometry. Every AminoLab lot is sent to an independent laboratory for mass spectrometry, covering identity, and HPLC, covering purity, and the printed lot number brings up its report in our certificate of analysis lookup. Our guide to reading a peptide COA walks through what each result means.
For bench preparation, our retatrutide reconstitution calculator converts fill size and diluent volume into a concentration, while bacteriostatic water serves as the normal diluent. For incretin comparisons, many teams set a dual agonist such as research tirzepatide beside it, and our retatrutide and tirzepatide comparison contrasts the two trial safety profiles.
After those TGA cases, buying from a seller that shows its test data is simply common sense. There is no need to hunt for retatrutide near me listings either, because AminoLab keeps it in Australian stock and ships online to laboratories nationwide. Shop the lyophilised retatrutide vial in 10, 20 or 30 mg, or choose the 10 mg retatrutide pen when your group prefers to skip reconstitution. Before ordering, pull up your lot's certificate and check that the measured mass is retatrutide's and not semaglutide's. That one check catches a substituted product before a vial is ever opened.
AminoLab sells retatrutide to adults 18 and over for laboratory research only. Giving it to people or animals is not permitted, and this guide contains no medical or dosing guidance.
Every trial so far puts digestive problems first, chiefly nausea, diarrhoea, vomiting and constipation. In TRIUMPH-1, 42.4% of people on 12 mg had nausea, versus 14.8% given placebo. Events were usually mild or moderate, became more frequent at higher doses and gathered in the dose-escalation weeks.
Not yet. No regulator, the TGA included, has approved it. Results from phases 2 and 3 resemble the wider incretin class apart from dysesthesia showing up at higher doses, but long-term, cardiovascular outcome and rare-event data are still lacking. Outside a clinical trial, the TGA says it should not be used.
Published trials so far show no cancer signal in people, but they have not run long enough to exclude rare or slow effects. In the US, related GLP-1 drugs are labelled with warnings based on rodent thyroid C-cell tumours. One 2025 mouse experiment saw tumours grow more slowly on retatrutide, which remains preclinical.
Phase 2 obesity data showed a dose-linked rise in resting pulse that was greatest around week 24 and faded afterwards. Nobody yet knows whether heart attack or stroke risk changes, as TRIUMPH-3 was too small to tell and TRIUMPH-Outcomes, which includes Australian hospital sites, has not finished.
The word describes skin that tingles, burns or feels oversensitive to touch. It first stood out in phase 3, where TRIUMPH-4 counted it in 20.9% of the 12 mg arm, 8.8% of the 9 mg arm and 0.7% of the placebo arm. Mild cases were the norm and rarely led people to stop, and the cause is still unexplained.
Order online from AminoLab, which holds retatrutide in Australian stock and ships to research groups nationwide in three vial fills or a ready-made pen. Insist on a published independent identity result for the specific lot, because the TGA has found retatrutide-labelled products that contained a different drug entirely.
10 mg vial, 60 capsules
50 mg vial, 100 mg vial
10 mg vial
3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe
Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.
Leave